RESUMEN
We report the results of non-myeloablative (NM) and myeloablative (MA) conditioning for haematopoietic cell transplantation in 207 consecutive AML patients at a single institution. A total of 122 patients were transplanted in first CR (CR1) and 67 in second CR (CR2). MA conditioning was given to 60 patients in CR1 and 50 in CR2. NM conditioning was given to 62 patients in CR1 and 17 patients in CR2. MA patients in CR1 experienced more acute GVHD than NM patients, 60.5% versus 22.9%, but the 5-year post transplant cumulative TRM was not different. Relapse incidence at 5 years in CR1 patients was 23.7% which is not statistically different from 28.5% in NM patients. Leukaemia-free survival at 5 years in CR1 patients was 57.7% after MA conditioning and 58.3% after NM conditioning. No statistical difference in overall 5-year survival after MA or NM conditioning was observed in CR1 patients (63.9 versus 64%) and CR2 patients (51.2 versus 64.7%). Durable remission can be obtained in older patients with AML in remission after NM conditioning, which may also be applicable to younger patients.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas/métodos , Leucemia Mieloide Aguda/terapia , Acondicionamiento Pretrasplante/métodos , Adolescente , Adulto , Terapia Combinada , Ciclofosfamida/administración & dosificación , Femenino , Humanos , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/radioterapia , Leucemia Mieloide Aguda/cirugía , Donadores Vivos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Estudios Retrospectivos , Sobrevivientes , Trasplante Homólogo , Irradiación Corporal Total , Adulto JovenRESUMEN
BACKGROUND: Allogeneic hematopoietic cell transplantation (allo-HCT) has been proposed as treatment for multiple sclerosis (MS) and other autoimmune diseases. AIMS: To describe the effects of allo-HCT on the course of MS in a 49-year-old woman with longstanding progressive MS who was treated with allo-HCT for follicular lymphoma. METHODS: Non-myeloablative conditioning allo-HCT, examination for IgG oligoclonal bands and measurement of CXCL13 and matrix metalloproteinase-9 (MMP-9) concentration in the cerebrospinal fluid (CSF). RESULTS: Despite the disappearance of oligoclonal bands in CSF, disease progression and CSF inflammation was observed. CONCLUSIONS: We hypothesize that CXCL13 and MMP-9 detected in CSF may reflect ongoing, pathogenic immune activation even after the eradication of intrathecal IgG synthesis. This suggests that progressive MS may depend more on innate than on adaptive immune activation.
RESUMEN
Minor histocompatibility antigens (mHags) encoded by the Y-chromosome (H-Y-mHags) are known to play a pivotal role in allogeneic haematopoietic cell transplantation (HCT) involving female donors and male recipients. We present a new H-Y-mHag, YYNAFHWAI (UTY(139-147)), encoded by the UTY gene and presented by HLA-A*24:02. Briefly, short peptide stretches encompassing multiple putative H-Y-mHags were designed using a bioinformatics predictor of peptide-HLA binding, NetMHCpan. These peptides were used to screen for peptide-specific HLA-restricted T cell responses in peripheral blood mononuclear cells obtained post-HCT from male recipients of female donor grafts. In one of these recipients, a CD8+ T cell response was observed against a peptide stretch encoded by the UTY gene. Another bioinformatics tool, HLArestrictor, was used to identify the optimal peptide and HLA-restriction element. Using peptide/HLA tetramers, the specificity of the CD8+ T cell response was successfully validated as being HLA-A*24:02-restricted and directed against the male UTY(139-147) peptide. Functional analysis of these T cells demonstrated male UTY(139-147) peptide-specific cytokine secretion (IFNγ, TNFα and MIP-1ß) and cytotoxic degranulation (CD107a). In contrast, no responses were seen when the T cells were stimulated with patient tumour cells alone. CD8+ T cells specific for this new H-Y-mHag were found in three of five HLA-A*24:02-positive male recipients of female donor HCT grafts available for this study.
Asunto(s)
Antígenos de Histocompatibilidad Menor/inmunología , Proteínas Nucleares/inmunología , Secuencia de Aminoácidos , Células Sanguíneas/trasplante , Linfocitos T CD8-positivos/inmunología , Epítopos/inmunología , Femenino , Antígeno HLA-A24/inmunología , Humanos , Masculino , Proteínas Nucleares/química , Trasplante HomólogoAsunto(s)
Aldehídos/efectos adversos , Alérgenos/efectos adversos , Ciclohexenos/efectos adversos , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/epidemiología , Pruebas del Parche/estadística & datos numéricos , Perfumes/administración & dosificación , Dinamarca/epidemiología , Femenino , Humanos , Masculino , Pruebas del Parche/métodos , PrevalenciaRESUMEN
Since the late 1940's the annual number of cataract extractions performed at the Eye Department of the Municipal Hospital of Copenhagen has quintupled. This increase has been followed by a tendency towards stabilisation. An increase of the potential cataract clientele by about 60 per cent and an extended indication for operation are considered obvious causes of this rise, to which must be added an increase-inducing factor due to the popularisation of a visual rehabilitating operation in a community with a relative preponderance of old inhabitants. An attempt at a statistical calculation of the percentage of the population subjected to cataract extraction in a defined area, related to age, is presented. This calculation may be of some guidance in the planning of ophthalmosurgical facilities.